What is Zacks Research's Forecast for BMY FY2026 Earnings?

Key Points

• Zacks Research raised its FY2026 EPS forecast for Bristol Myers Squibb to $6.86, up from $6.85 but below the analyst consensus of $6.95. The estimate remains within the company’s FY2026 guidance range of $6.75–$7.00.
• Bristol Myers Squibb’s latest quarterly results exceeded expectations, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus $11.74 billion expected. Revenue increased 5.7% year over year.
• Analyst sentiment is broadly positive but cautious: the stock has a “Moderate Buy” consensus rating and a $66.33 average price target, while pipeline advances are balanced by patent-dispute risks and generic pressure on legacy products.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities researchers at Zacks Research raised their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Friday, September 11th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $6.86 per share for the year, up from their prior forecast of $6.85. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb's Q4 2026 earnings at $1.65 EPS, Q2 2027 earnings at $1.74 EPS, Q4 2027 earnings at $1.53 EPS, FY2027 earnings at $6.23 EPS, Q1 2028 earnings at $1.47 EPS, Q2 2028 earnings at $1.37 EPS and FY2028 earnings at $5.17 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Other equities analysts have also recently issued research reports about the stock. Royal Bank Of Canada boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the stock an "equal weight" rating in a report on Friday, July 31st. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. Finally, Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.33.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $63.52 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a fifty day moving average of $63.61 and a 200-day moving average of $60.07. The stock has a market capitalization of $129.76 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by company insiders.

Institutional Trading of Bristol Myers Squibb

Large investors have recently modified their holdings of the business. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 4,935 shares during the period. Sivia Capital Partners LLC lifted its stake in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after acquiring an additional 2,786 shares during the period. United Bank boosted its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $405,000. 76.41% of the stock is owned by institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising multiple myeloma CAR-T results strengthen the pipeline. Bristol Myers said experimental therapy arlocabtagene autoleucel (arlo-cel) met the primary goal of a mid-stage trial in heavily pretreated multiple myeloma patients. The statistically significant and clinically meaningful improvement in overall response rate could support the company’s long-term oncology growth prospects. Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
• Positive Sentiment: Growth brands and pipeline progress remain supportive. An analyst review noted that Bristol Myers’ newer growth products and research pipeline are helping drive momentum, contributing to a reported 19.4% year-to-date gain before the latest weakness. BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• Neutral Sentiment: Analyst stance remains cautious. Scotiabank maintained a Hold rating, suggesting the positive pipeline developments are not yet sufficient to prompt a more bullish view.
• Neutral Sentiment: Long-term psoriasis study data add information but not an immediate catalyst. Bristol Myers provided an update on an ongoing long-term psoriasis study; the available report did not identify a major change to near-term earnings expectations. Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors
• Negative Sentiment: Patent-dispute uncertainty weighs on sentiment. RBC said Cytokinetics has an advantage in its patent dispute with Bristol Myers, raising potential legal and competitive concerns. Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
• Negative Sentiment: Downside hedging and portfolio pressure are visible. Investors purchased about 44,454 BMY put options, roughly 71% above average put volume. Analysts also continue to flag generic pressure on the legacy portfolio, while the stock recently underperformed the broader market.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.